Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 345

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 345
---
 transplanted adipose tissue. The results of these procedures can
be unpredictable and can result in the need for costly secondary surgeries. Secondary surgeries are limited by the patients’ available
volume of autologous tissue and problems with tissue harvesting and scarring at the donor site. As a result, we believe that there is
a significant need for a biomaterial solution that provides the ease of use, delivery and availability benefits of synthetic implants
with the benefits of autologous adipose tissue.

When tissues
are processed to remove biomaterials such as viable cells, the isolated and preserved ECM- based biomaterials, which are known as matrixes
or scaffolds, provide mechanical support and biological signals for cell migration and tissue development. The ECM’s biological
signals, including growth factors and ECM-associated vesicles, promote cell migration and tissue development for the formation of viable
and potentially permanent new tissue. Although surgical soft tissue reconstruction is often done with autologous adipose tissue, there
is currently no allogenic biomaterial that is FDA-approved and that mimics or is derived from native adipose tissue.

| 180 |

LBI-101 is human
allograft adipose tissue minimally processed to remove oil and cells while maintaining the integrity of the matrix with the intent to
address the issues of the specific and nonspecific inflammatory responses. The proprietary manufacturing process preserves the remaining
extracellular components of the extracellular matrix of the adipose tissue, primarily type 1 collagen. The acellular matrix is processed
without damage to the matrix components and is designed to be injected. The allograft is designed to function as a physical framework
to produce tissue-like volume that can support cellular infiltration and new tissue formation at the implant site.

| 5 | Fortune Business Insights, Medical Device/Dermal Fillers Market. Report ID: FBI100939, https://www.fortunebusinessinsights.com/industry-reports/dermal-fillers-market-100939 |

| 6 | Anderson, A. E., Wu, I., Parrillo, A. J., Wolf, M. T., Maestas, D. R., Graham, I., Tam, A. J., Payne,                                                     
 R. M., Aston, J., Cooney, C. M., Byrne, P., Cooney, D. S., & Elisseeff, J. H. (2022). An immunologically active, adipose-derived extracellular            
 matrix biomaterial for soft tissue reconstruction: concept to